DMK Pharmaceuticals is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. DMK’s ...

DMK Pharmaceuticals (NASDAQ:DMK) is a textbook example of how a promising company can go down the drain in a matter of years, months, or even days. I am bearish on DMK stock and hope that investors ...

DMK Pharmaceuticals Corporation (NASDAQ:DMK) shares are trading higher Thursday after the company announced that it has regained the full rights to commercialize Zimhi (naloxone) after the termination ...